R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	1,115	1,128	1,069	991.48	1,522	361.6
Trading Asset Securities	556.76	620.12	707.61	712.39	-	-
Cash & Short-Term Investments	1,672	1,748	1,776	1,704	1,522	361.6
Cash Growth	-2.85%	-1.61%	4.25%	11.93%	321.00%	23.07%
Accounts Receivable	425.01	337.36	279.37	238.31	222.26	179.76
Other Receivables	6.27	8.75	7.52	7.67	7.29	8.78
Receivables	431.28	346.11	286.89	245.98	229.55	188.54
Inventory	53.08	59.02	65.23	51.26	53.01	43.27
Other Current Assets	6.1	2.48	3.39	5.1	3.75	11.71
Total Current Assets	2,163	2,155	2,132	2,006	1,809	605.11
Property, Plant & Equipment	48.16	51.37	55.58	40.93	52.45	33.75
Long-Term Investments	79.3	79.49	32.78	-	-	-
Goodwill	85.6	85.6	85.6	0.08	0.08	0.08
Other Intangible Assets	14.48	16.25	19.43	17.93	12.83	17.88
Long-Term Deferred Tax Assets	11.88	9.96	8.61	7.62	7.28	4.16
Long-Term Deferred Charges	0.95	1.68	2.4	1.04	1.83	2.51
Other Long-Term Assets	0.02	-	-	-	-	13.98
Total Assets	2,403	2,400	2,336	2,074	1,883	677.47

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	46.58	46.17	50.97	40.87	32.2	-
Accrued Expenses	44.77	37.52	34.06	32.14	32.89	49.36
Short-Term Debt	-	-	55.14	-	-	-
Current Portion of Leases	8.01	10.14	8.91	5.99	9.55	7.08
Current Income Taxes Payable	3.09	7.81	6.91	7.17	4.08	2.86
Current Unearned Revenue	200	223.25	235.12	200.42	183.22	150.9
Other Current Liabilities	69.98	60.18	45.39	27.78	18.57	24.24
Total Current Liabilities	372.44	385.07	436.49	314.36	280.52	234.43
Long-Term Leases	8.31	7.73	7.81	2.88	6.13	3.9
Long-Term Unearned Revenue	1.6	1.6	0.71	-	-	1
Long-Term Deferred Tax Liabilities	3.5	3.73	4.25	1.76	2.42	0.05
Other Long-Term Liabilities	10.16	25.75	50.83	0.16	0.27	0.28
Total Liabilities	396	423.89	500.09	319.17	289.35	239.66

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	96.58	96.58	96.58	96	60	45
Additional Paid-In Capital	1,067	1,056	1,057	1,057	1,079	17.71
Retained Earnings	867.78	838.67	717.07	596.05	448.52	359.71
Treasury Stock	-32.01	-22.95	-37.96	-	-	-
Comprehensive Income & Other	-0.75	-0.61	-0.08	-0.41	-0.15	0.12
Total Common Equity	1,999	1,968	1,833	1,748	1,588	422.53
Minority Interest	8.44	7.56	3.62	6.24	5.97	15.28
Shareholders' Equity	2,007	1,976	1,836	1,755	1,594	437.81
Total Liabilities & Equity	2,403	2,400	2,336	2,074	1,883	677.47

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	16.32	17.87	71.86	8.86	15.68	10.98
Net Cash (Debt)	1,656	1,730	1,704	1,695	1,507	350.62
Net Cash Growth	-2.85%	1.49%	0.56%	12.50%	329.70%	19.33%
Net Cash Per Share	17.19	18.07	17.87	17.66	18.33	4.88
Filing Date Shares Outstanding	95.8	95.99	95.14	96	96	72
Total Common Shares Outstanding	95.8	95.99	95.14	96	96	72
Working Capital	1,790	1,770	1,695	1,692	1,528	370.68
Book Value Per Share	20.86	20.50	19.26	18.21	16.54	5.87
Tangible Book Value	1,899	1,866	1,727	1,730	1,575	404.56
Tangible Book Value Per Share	19.82	19.44	18.16	18.02	16.40	5.62
Buildings	14.43	14.43	14.43	14.43	14.43	-
Machinery	81.19	80.38	78.02	57.08	56.03	51.4

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 18, 2026

Data Sources Report a data error